These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 8923365)
1. Increased pigmentation in scleroderma. Pope JE; Shum DT; Gottschalk R; Stevens A; McManus R J Rheumatol; 1996 Nov; 23(11):1912-6. PubMed ID: 8923365 [TBL] [Abstract][Full Text] [Related]
2. Localization of endothelin-1 and its binding sites in scleroderma skin. Vancheeswaran R; Azam A; Black C; Dashwood MR J Rheumatol; 1994 Jul; 21(7):1268-76. PubMed ID: 7525957 [TBL] [Abstract][Full Text] [Related]
3. Quantification of fetal microchimeric cells in clinically affected and unaffected skin of patients with systemic sclerosis. Sawaya HH; Jimenez SA; Artlett CM Rheumatology (Oxford); 2004 Aug; 43(8):965-8. PubMed ID: 15199216 [TBL] [Abstract][Full Text] [Related]
4. Damage of cutaneous peripheral nervous system evolves differently according to the disease phase and subset of systemic sclerosis. Manneschi LI; Del Rosso A; Milia AF; Tani A; Nosi D; Pignone A; Generini S; Giacomelli R; Cerinic MM Rheumatology (Oxford); 2005 May; 44(5):607-13. PubMed ID: 15728417 [TBL] [Abstract][Full Text] [Related]
5. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. Furst DE; Clements PJ; Steen VD; Medsger TA; Masi AT; D'Angelo WA; Lachenbruch PA; Grau RG; Seibold JR J Rheumatol; 1998 Jan; 25(1):84-8. PubMed ID: 9458208 [TBL] [Abstract][Full Text] [Related]
6. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059 [TBL] [Abstract][Full Text] [Related]
7. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Santiago B; Galindo M; Rivero M; Pablos JL Arthritis Rheum; 2001 Jul; 44(7):1667-76. PubMed ID: 11465719 [TBL] [Abstract][Full Text] [Related]
8. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Kawaguchi Y; Takagi K; Hara M; Fukasawa C; Sugiura T; Nishimagi E; Harigai M; Kamatani N Arthritis Rheum; 2004 Jan; 50(1):216-26. PubMed ID: 14730619 [TBL] [Abstract][Full Text] [Related]
9. Variations of neuronal nitric oxide synthase in systemic sclerosis skin. Ibba-Manneschi L; Niissalo S; Milia AF; Allanore Y; Del Rosso A; Pacini A; Manetti M; Toscano A; Cipriani P; Liakouli V; Giacomelli R; Kahan A; Konttinen YT; Matucci-Cerinic M Arthritis Rheum; 2006 Jan; 54(1):202-13. PubMed ID: 16385516 [TBL] [Abstract][Full Text] [Related]
10. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16. Mondini M; Vidali M; De Andrea M; Azzimonti B; Airò P; D'Ambrosio R; Riboldi P; Meroni PL; Albano E; Shoenfeld Y; Gariglio M; Landolfo S Arthritis Rheum; 2006 Dec; 54(12):3939-44. PubMed ID: 17133607 [TBL] [Abstract][Full Text] [Related]
11. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis. Yanaba K; Muroi E; Yoshizaki A; Hara T; Ogawa F; Shimizu K; Yozaki M; Hasegawa M; Fujimoto M; Takehara K; Sato S J Rheumatol; 2009 Sep; 36(9):1917-23. PubMed ID: 19605674 [TBL] [Abstract][Full Text] [Related]
12. HLA-G expression in the skin of patients with systemic sclerosis. Wastowski IJ; Sampaio-Barros PD; Amstalden EM; Palomino GM; Marques-Neto JF; Crispim JC; Biral AC; Rassi DM; Carosella ED; Moreau P; Donadi EA J Rheumatol; 2009 Jun; 36(6):1230-4. PubMed ID: 19369464 [TBL] [Abstract][Full Text] [Related]
13. Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Flavahan NA; Flavahan S; Liu Q; Wu S; Tidmore W; Wiener CM; Spence RJ; Wigley FM Arthritis Rheum; 2000 Aug; 43(8):1886-90. PubMed ID: 10943881 [TBL] [Abstract][Full Text] [Related]
14. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc. Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419 [TBL] [Abstract][Full Text] [Related]
15. Expression of osteonectin and matrix Gla protein in scleroderma patients with and without calcinosis. Davies CA; Jeziorska M; Freemont AJ; Herrick AL Rheumatology (Oxford); 2006 Nov; 45(11):1349-55. PubMed ID: 17050587 [TBL] [Abstract][Full Text] [Related]
16. Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma). Sprott H; Müller-Ladner U; Distler O; Gay RE; Barnum SR; Landthaler M; Schölmerich J; Lang B; Gay S J Rheumatol; 2000 Feb; 27(2):402-4. PubMed ID: 10685805 [TBL] [Abstract][Full Text] [Related]
17. Cardiac magnetic resonance imaging detects subclinical right ventricular impairment in systemic sclerosis. Bezante GP; Rollando D; Sessarego M; Panico N; Setti M; Filaci G; Molinari G; Balbi M; Cutolo M; Barsotti A; Indiveri F; Ghio M J Rheumatol; 2007 Dec; 34(12):2431-7. PubMed ID: 17985401 [TBL] [Abstract][Full Text] [Related]
18. Cutaneous side effects from laser treatment of the skin: skin cancer, scars, wounds, pigmentary changes, and purpura--use of pulsed dye laser, copper vapor laser, and argon laser. Haedersdal M Acta Derm Venereol Suppl (Stockh); 1999; 207():1-32. PubMed ID: 10605602 [TBL] [Abstract][Full Text] [Related]
19. The scleroderma neck sign. Weinstein CL; Miller MH; Kossard S; Littlejohn GO J Rheumatol; 1989 Dec; 16(12):1533-5. PubMed ID: 2625682 [TBL] [Abstract][Full Text] [Related]
20. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Kissin EY; Merkel PA; Lafyatis R Arthritis Rheum; 2006 Nov; 54(11):3655-60. PubMed ID: 17075814 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]